RxSight

RxSight's mission is to revolutionize the premium cataract surgery experience by enabling post-operative customization of visual outcomes. The company has achieved a significant milestone with the FDA approval and commercialization of its Light Adjustable Lens (LAL) and Light Delivery Device (LDD) system, a first-in-class technology platform. Its strategy focuses on driving surgeon adoption in the large U.S. cataract market, expanding into international regions, and leveraging its unique platform to potentially address other refractive indications. RxSight is a publicly traded company (NASDAQ: RXST) positioned at the intersection of medical devices and personalized ophthalmology.

A proprietary, integrated platform consisting of the implantable Light Adjustable Lens (LAL), made from a photosensitive silicone material, and the Light Delivery Device (LDD), which uses targeted UV light to non-invasively adjust the lens's power after cataract surgery.

RxSight competes in the premium IOL market against giants like Alcon, Johnson & Johnson Vision, and Bausch + Lomb. Its unique, defensible advantage is the post-operative adjustability of its lens, a feature no other FDA-approved IOL possesses. It competes on outcome certainty and customization rather than directly on the fixed optical properties (multifocality, EDOF) of incumbent lenses.